UNC-Chapel Hill researchers used EMERSE to find patients with rheumatological diseases who received immune checkpoint inhibitors: "anti-rheumatic therapy did not prevent disease flares or new onset irAEs, but did not negatively impact malignancy outcomes."
ICI治療の転機に影響ないんだ。 Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy - PubMed https://t.co/Zh8AyQUkpl
Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy https://t.co/0dbRO1ccgf https://t.co/IJ8LiuCR4Z